Lurbinectedin
- Generic Name
- Lurbinectedin
- Brand Names
- Zepzelca, 赞必佳
- Drug Type
- Small Molecule
- Chemical Formula
- C41H44N4O10S
- CAS Number
- 497871-47-3
- Unique Ingredient Identifier
- 2CN60TN6ZS
- Background
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate Ecteinascid...
- Indication
Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
- Associated Conditions
- Metastatic Lung Small Cell Carcinoma
- Associated Therapies
- -
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA
- Conditions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT04291937
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 42
- Registration Number
- NCT03213301
- Locations
- 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭Regionalspital Thun, Thun, Switzerland
🇮🇹A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 320
- Registration Number
- NCT02611024
- Locations
- 🇩🇪
Helios Klinikum Berlin Buch, Berlin, Germany
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇮🇹Campus Biomedico, Roma, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.